Targeting WEE1 in tumor-associated dendritic cells potentiates antitumor immunity via the cGAS/STING pathway

Ian-Ian Ng1, Zhihua Zhang2, Kaimin Xiao3

  • 1State Key Laboratory of Molecular Oncology, School of Pharmaceutical Sciences, Tsinghua University, Beijing 100084, China.

Cell Reports
|May 21, 2025
PubMed

Insights

DNA damage in tumor-associated dendritic cells (TADCs) suppresses antitumor immunity. Inhibiting WEE1 kinase in TADCs activates them, enhancing immune responses and improving tumor control, offering a new cancer immunotherapy strategy.

Area of Science:

  • Immunology
  • Cancer Biology
  • Molecular Oncology

Background:

  • DNA damage impacts cancer progression and immune function, but its effects on immune cells are understudied.
  • Tumor-associated dendritic cells (TADCs) exhibit DNA damage and upregulated WEE1 kinase, a DNA repair regulator.
  • DNA damage can paradoxically stimulate dendritic cell (DC) activation.

Purpose of the Study:

  • To investigate the role of WEE1 signaling in DNA damage repair within TADCs in the tumor microenvironment.
  • To explore the therapeutic potential of targeting WEE1 in TADCs for enhancing antitumor immunity.

Main Methods:

  • Observation of DNA damage and WEE1 expression in TADCs.
  • Assessment of TADC activation via the cGAS/STING pathway.
  • Evaluation of cytokine expression (IL-12, type I interferon) following WEE1 inhibition.
  • Analysis of WEE1 inhibition's effects on DC vaccines and immune checkpoint blockade therapy.

Main Results:

  • Significant DNA damage and WEE1 upregulation were observed in TADCs.
  • WEE1 inhibition in TADCs led to activation via the cGAS/STING pathway.
  • Inhibition increased IL-12 and type I interferon, boosting antitumor immune response and tumor control.
  • WEE1 inhibition enhanced DC vaccine efficacy and synergized with immune checkpoint blockade.

Conclusions:

  • WEE1 signaling in TADCs plays a critical role in DNA damage repair, suppressing antitumor immunity within the tumor microenvironment.
  • Targeting WEE1 in DCs is a promising strategy to enhance T cell activation and improve cancer immunotherapy outcomes.

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
457
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.5K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
823